KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Safety, acceptability, and adherence to dapivirine vaginal ring and oral pre-exposure prophylaxis for HIV prevention in the second trimester of pregnancy: a multicountry, open-label, phase 3b randomised trial.

Felix G Mhlanga, Daniel W Szydlo, Ashley J Mayo, Katherine Bunge, Lee Fairlie, Clemensia Nakabiito, Petina Musara, Nyaradzo M Mgodi, Sufia Dadabhai, Rachel Scheckter, Peter L Anderson, Mark A Marzinke, Catherine Chappell, Luis A Gadama, Barbra A Richardson, Jeanna M Piper, Sharon L Hillier, MTN-042 DELIVER study team

Lancet HIV 13(3) e176-e184

PMID41687672
PMCIDPMC13332517
DOI10.1016/S2352-3018(25)00307-8
发表日期2026-02-13
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:ROC 图。
摘要

摘要

BACKGROUND: Pregnant women are at a four times higher risk of HIV per coital act than non-pregnant women. MTN-042/DELIVER was a phase 3b randomised study of dapivirine vaginal ring (DVR) and oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine to assess safety, adherence, and acceptability when used during pregnancy. Our hypothesis was that both DVR and oral PrEP would be safe and well tolerated when started early in the second trimester and continued until delivery. METHODS: In MTN-042/DELIVER, an open-label, phase 3b randomised trial, healthy pregnant women without HIV and aged 18-40 years from Malawi, South Africa, Uganda, and Zimbabwe were enrolled and randomly allocated (4:1) to open-label monthly DVR PrEP or daily oral PrEP. Women were enrolled between 12 weeks' and 29 weeks' gestation. Product use continued until delivery or 42 weeks' gestation. The primary outcomes for safety following exposure to study product were a composite of all serious adverse events, including maternal deaths, all grade 3 or higher adverse events, and pregnancy outcomes stratified as term (≥37+0 weeks), preterm (<37+0 weeks), and pregnancy loss before 20 weeks' gestation. Pregnancy complications and adverse events were summarised with descriptive statistics. This study is registered with ClinicalTrials.gov, NCT03965923. FINDINGS: Between July 12, 2022, and Jan 12, 2023, 251 mothers were enrolled, with 202 randomly allocated to receive DVR PrEP and 49 to receive oral PrEP. The median age was 24·0 years (IQR 22·0-29·0) and the median gestational age was 23·7 weeks (19·9-26·3). 28 mothers (11%) had safety events under the composite study primary outcome (all serious adverse events plus all grade 3 or higher adverse events), none of which was related to product use. No maternal deaths or HIV seroconversions occurred. There were 247 pregnancy outcomes of which 233 (94%) were at term (≥37+0 weeks). Pregnancy complications were uncommon, and none was infectious. INTERPRETATION: Adverse pregnancy outcomes related to DVR and oral PrEP use were uncommon among women starting PrEP in the second trimester. These findings support the use of these preventive approaches during pregnancy. FUNDING: US National Institutes of Health.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1: Consort Diagram for cohort 3 participants screened and enrolled into the MTN-042/DELIVER study
非 KM Figure
Figure 2Figure 2: Maternal adherence to DVR and TDF/FDC measured by residual DPV and intraerythrocytic TFV-DP at various gestational ages for the MTN-042/DELIVER cohort 3 participants. Dapivirine was measured in rings returned after use. Tenofovir diphosphate (TFV-DP) was measured from dried blood spots.
非 KM Figure